Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, ...

Patients with presyncope and those with syncope in the ED have similar 30‑day serious cardiac outcomes, although patients ...

A large study suggests taking progesterone before pregnancy — not just after conception — may help reduce the risk for ...

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...

General anesthesia leads to better functional outcomes than conscious sedation in stroke patients with large vessel occlusion ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of ...

Weekly intramuscular injections of rotigotine extended-release microspheres are linked to significant symptom improvement in ...

New draft guidelines on the definition of new active substances don’t apply to deutetrabenazine, the European drug regulator ...

Midwives and family physicians are essential to support mothers facing hypogalactia and maintain WHO-recommended exclusive ...